Takara Bio Group Business
Takara Bio aims to be a biologics development company that continuously creates new modalities (treatments) by developing platform technology for biologics through our core businesses of Reagents/Instruments and CDMO*.
* CDMO (Contract Development and Manufacturing) refers to provision of contract services for drug development and manufacturing, in all steps of the process from formulation to final manufacturing, for clients such as pharmaceutical companies. Takara Bio provides CDMO services focused on regenerative medicine products such as gene therapy.
Takara Bio supports academic and corporate life sciences activities by offering reagents, instruments, and CDMO services.
Research Reagents and Scientific Instruments
TaKaRa®’s PCR machine, Thermal Cycler Dice® Real Time System III
Takara Bio sells reagents and instruments under three unique brands: TaKaRa®, Clontech®, and Cellartis®. These brands meet a wide range of needs in the life sciences field throughout the world, from basic and cutting-edge research to industrial applications.
Product under the TaKaRa® brand are developed and sold by Takara Bio, and the brand offers an extensive lineup that covers all fields of bio research, including genetic, protein, and cellular engineering. It got its start as the first brand in Japan to develop and market restriction enzymes, back in 1979. PCR systems (machines and reagents) were soon added to the product lineup as well. Over its more than 40 years of history, TaKaRa® has added more and more products, and provides powerful support to bio researchers. In 2020, we added in vitro diagnostics using PCR technology, further expanding our scope.
Our Clontech® brand was developed by the former Clontech Laboratories (now Takara Bio USA, Inc.) and primarily offers products for advanced molecular biological research. It has particularly strong product offerings for functional genomic analysis, protein interaction research, and DNA library construction. We are developing outstanding products for the rapidly expanding market of next-generation sequencers under this brand. In the area of scientific instruments, we are developing and marketing an ultralow input genetic analysis system for single-cell analysis.
Our Cellartis® brand is developed by a company formerly called Cellartis AB (now Takara Bio Europe AB) founded by members of the University of Gothenburg in Sweden. Its product lineup includes cell products such as ES and iPS cells, as well as products for advanced stem cell research such as products for cell culturing.
Offers a wide range of products for genetic engineering and all other kinds of biotechnology research applications.
- Genetic research reagents
- Genetic testing kits
- Genome analysis services
- Products related to novel coronavirus testing
Has a lineup of products optimized for advanced research in fields such as molecular and cell biology.
- Analytical reagents for next-generation sequencers
- Single-cell analysis systems
- Gene expression research reagents
- Fluorescent proteins series for gene function analysis
- Genome-editing research reagents
Offers iPS cell products and other products used in stem cell research, as well as contract services in the field.
- iPS cell research reagents
- Products for stem cell culturing and induction of differentiation
(CDMO: Contract Development & Manufacturing Organization)
Center for Gene and Cell Processing
Center for Gene and Cell Processing II
Through our CDMO business, Takara Bio provides contract services for drug development and manufacturing, in all steps of the process from formulation to final manufacturing, for clients such as pharmaceutical companies. Our two top fields of focus are services related to regenerative medicine products such as gene therapy, and services related to genetic analysis and testing, such as genome sequencing and genetic analysis for regenerative medicine products.
At our Center for Gene and Cell Processing, which is the hub for our CDMO business, we are enhancing our capabilities for manufacturing and quality control testing for vectors and transduced cells. As we expand our facilities, we are urgently working to meet the growing demands from CDMO services by developing efficient expansion culture methods and technology to scale up vector production, as well as by automating manufacturing processes.
In vitro Diagnostics Business
Takara Bio develops, manufactures, and sells in vitro diagnostic reagents that detect viruses and other nuclear acids using the PCR method.
SARS-CoV-2 Nucleic acid detection kit
Nucleic acid detection kit
We are selling kits that detect the RNAs of the novel coronavirus (SARS-CoV-2) using real time RT-PCR methods. A feature of this kit is that it eliminates the need for RNA purification by adopting a simplified extraction method, which reduces testing times compared to standard PCR testing methods. In addition, to detect internal control simultaneously, we can prevent false negative characterization due to PCR inhibition, which helps to assist in the diagnosis of the novel coronavirus infectious disease (COVID-19).
Gene Therapy Business
We are developing platform technology for drug development to maximize the value of projects out-licensed to pharmaceutical companies and develop new clinical projects that seek to solve current issues with gene therapy.
Research image of gene therapy
In close collaboration with our business partners, we structure systems for manufacturing and supply of regenerative medicine products with an eye to bringing them to market, and also work on expanding indications of approved products.
New Clinical Development Projects
We are planning to start clinical trials of our new CAR gene therapy, which is currently being investigated in preclinical trials, in fiscal 2023.
Developing platform technology for during development
We are putting effort into developing platform technology for drug development in areas such as gene therapy.
● Establish methods for mass production of viral vectors such as AAVs
● Develop next-generation CAR gene therapy for solid cancers
● Develop viral vectors for new organ-specific in vivo gene therapies
● Develop next-generation TCR/CAR gene therapy with a persistent antitumor effect